PRN-1008の新興薬剤に関する洞察と市場予測：2032年

リルザブルチニブ（PRN-1008）は、経口投与のブルトン型チロシンキナーゼ（BTK）の可逆的共有結合阻害剤です。BTKは、B細胞受容体（BCR）、Fcガンマ受容体、Fcイプシロン受容体経路の下流に位置する必須のシグナル伝達要素です。BTKの活性化はB細胞の活性化と成熟に不可欠です。BTKはまた、Fc受容体シグナル伝達を通じて、マクロファージ、好中球、肥満細胞などのその他の免疫細胞の抗体媒介活性化も制御しています。この薬剤候補は、B細胞を枯渇させることなく、効果的かつ安全にB細胞の機能を調節できる即効性の経口治療薬であり、自己免疫疾患や炎症性疾患の治療における大きな進歩になると期待されています。

前臨床試験において、PRN1008は抗CD41誘発ITPモデルマウスにおいて、用量依存的に有意な血小板減少抑制効果を示しました。PRN1008は、抗体駆動型ラット関節炎モデルおよび自然発症の自己抗体介在性イヌ天疱瘡において、迅速かつ有意な抗炎症作用を示しました。前臨床データは、PRN1008が脾臓マクロファージにおける自己抗体／Fcガンマレセプターシグナル伝達の阻害を介して血小板破壊を減少させ、B細胞活性化における自己抗体生成効果に影響を与え、ITPにおける血小板損失を減少させる可能性を示唆しています。

当レポートでは、主要7ヶ国におけるPRN-1008市場について調査し、市場の概要とともに、2024年～2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 免疫性血小板減少症（ITP）に対するPRN-1008の概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品概要

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 PRN-1008市場評価

• ITPに対するPRN-1008の市場展望
• 主要7ヶ国市場分析
  • 主要7ヶ国におけるITPに対するPRN-1008の市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: PRN-1008, Clinical Trial Description, 2023
• Table 2: PRN-1008, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: PRN-1008 Market Size in the 7MM, in USD million (2019-2032)
• Table 6: PRN-1008 Market Size in the US, in USD million (2019-2032)
• Table 7: PRN-1008 Market Size in Germany, in USD million (2019-2032)
• Table 8: PRN-1008 Market Size in France, in USD million (2019-2032)
• Table 9: PRN-1008 Market Size in Italy, in USD million (2019-2032)
• Table 10: PRN-1008 Market Size in Spain, in USD million (2019-2032)
• Table 11: PRN-1008 Market Size in the UK, in USD million (2019-2032)
• Table 12: PRN-1008 Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: PRN-1008 Market Size in the 7MM, USD million (2019-2032)
• Figure 2: PRN-1008 Market Size in the United States, USD million (2019-2032)
• Figure 3: PRN-1008 Market Size in Germany, USD million (2019-2032)
• Figure 4: PRN-1008 Market Size in France, USD million (2019-2032)
• Figure 5: PRN-1008 Market Size in Italy, USD million (2019-2032)
• Figure 6: PRN-1008 Market Size in Spain, USD million (2019-2032)
• Figure 7: PRN-1008 Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: PRN-1008 Market Size in Japan, USD million (2019-2032)

“"PRN-1008 Emerging Drug Insight and Market Forecast - 2032" ” report provides comprehensive insights about PRN-1008 for immune thrombocytopenic purpura (ITP) in the seven major markets. A detailed picture of the PRN-1008 for ITP in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the PRN-1008 for ITP. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the PRN-1008 market forecast analysis for ITP in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in ITP.

Drug Summary:

Rilzabrutinib (PRN-1008) is an orally administered reversible covalent inhibitor of bruton tyrosine kinase (BTK). BTK is an essential signaling element downstream of the B-cell receptor (BCR), Fc-gamma receptor, and Fc-epsilon receptor pathways. BTK activation is critical for B-cell activation and maturation. BTK also regulates antibody-mediated activation of other immune cells, such as macrophages, neutrophils, and mast cells, through Fc receptor signaling. The drug candidate is a fast-acting, orally available therapy that could effectively and safely modulate B-cell function without depleting the B-cell and is expected to be a major advancement in treating autoimmune and inflammatory diseases.

In preclinical studies, PRN1008 demonstrated a significant dose-dependent platelet loss reduction in an anti-CD41-induced mouse model of ITP. PRN1008 showed rapid and significant anti-inflammatory effects in an antibody-driven rat arthus model and spontaneous autoantibody-mediated canine pemphigus foliaceus. The preclinical data suggest that PRN1008 could reduce platelet destruction via inhibition of autoantibody/Fc-gamma receptor signaling in splenic macrophages and affect autoantibody generation effects on B-cell activation to diminish platelet loss in ITP.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the PRN-1008 description, mechanism of action, dosage and administration, research and development activities in immune thrombocytopenic purpura (ITP).
• Elaborated details on PRN-1008 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the PRN-1008 research and development activities in ITP across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around PRN-1008.
• The report contains forecasted sales of PRN-1008 for ITP till 2032.
• Comprehensive coverage of the late-stage emerging therapies for ITP.
• The report also features the SWOT analysis with analyst views for PRN-1008 in ITP.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

PRN-1008 Analytical Perspective by DelveInsight

In-depth PRN-1008 Market Assessment

This report provides a detailed market assessment of PRN-1008 for immune thrombocytopenic purpura (ITP) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

PRN-1008 Clinical Assessment

The report provides the clinical trials information of PRN-1008 for ITP covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for immune thrombocytopenic purpura (ITP) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence PRN-1008 dominance.
• Other emerging products for ITP are expected to give tough market competition to PRN-1008 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of PRN-1008 in ITP.
• Our in-depth analysis of the forecasted sales data of PRN-1008 from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the PRN-1008 in ITP.

Key Questions:

• What is the product type, route of administration and mechanism of action of PRN-1008?
• What is the clinical trial status of the study related to PRN-1008 in immune thrombocytopenic purpura (ITP) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the PRN-1008 development?
• What are the key designations that have been granted to PRN-1008 for ITP?
• What is the forecasted market scenario of PRN-1008 for ITP?
• What are the forecasted sales of PRN-1008 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to PRN-1008 for ITP?
• Which are the late-stage emerging therapies under development for the treatment of ITP?

Table of Contents

1. Report Introduction

2. PRN-1008 Overview in ITP

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. PRN-1008 Market Assessment

• 5.1. Market Outlook of PRN-1008 in ITP
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of PRN-1008 in the 7MM for ITP
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of PRN-1008 in the United States for ITP
  • 5.3.2. Market Size of PRN-1008 in Germany for ITP
  • 5.3.3. Market Size of PRN-1008 in France for ITP
  • 5.3.4. Market Size of PRN-1008 in Italy for ITP
  • 5.3.5. Market Size of PRN-1008 in Spain for ITP
  • 5.3.6. Market Size of PRN-1008 in the United Kingdom for ITP
  • 5.3.7. Market Size of PRN-1008 in Japan for ITP

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options